Original article| Volume 34, ISSUE 1-2, P41-44, July 01, 1993

Download started.


Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder

      This paper is only available as a PDF. To read, Please Download here.


      Serotonin 1a and serotonin-2 receptors are implicated in anxiety. Serazepine (CGS-15040A, (R, S)-1,3,4,16b-Tetrahydro-2-methyl-2H, 10H-indolo[2,1-c] Pyrazino-[1,2-a][1,4] benzodiazepine-16-carboxylic acid, methyl ester hydrochloride]) is a representative of a novel pentacyclic ring system containing a stabilized indole. In chemical assays it was a highly specific inhibitor of serotonin (5-HT2) binding, and it was active in preliminary preclinical assays of anxiolytic potential. This multicenter trial of CGS-15040A in patients with generalized anxiety disorder demonstrated clinical anxiolytic effects consistent with established preclinical effects. Doses greater than or equal to 10 mg reduced Hamilton Anxiety Scale scores. However, the dose -response relationship was nonlinear. Effects appeared primarily related to the psychic components of anxiety.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ceulemans D.L.S.
        • Hoppenbrouwers M.L.J.A.
        • Gelders Y.G.
        • Reyntjens A.J.M.
        The Influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study versus lorazepam.
        Pharmacopsychiatry. 1985; 18: 303-305
        • Costall B.
        • Domeney A.M.
        • Gerraro
        Effects of the 5-HT receptor antagonist GR 30832 F, ICS 205930, and BRL 43694 in test for anxiolytic activity.
        Br J Pharmacol. 1987; 90: 195
        • Gelders Y.G.
        Thymosthenic agents a novel approach in the treatment of schizophrenia.
        Br J Psychiatry. 1989; 155: 33-36
        • Geller I.
        • Blum K.
        The effects of 5-HTP on parachlorophenylalanine (p-CPA) attenuation of “conflict” behavior.
        Eur J Pharmacol. 1970; 9: 319-324
        • Glennon R.A.
        Serotonin receptors clinical implications.
        Neurosci Biobehav Rev. 1990; 14: 35-47
        • Graeff G.G.
        • Schoenfeld R.I.
        Tryptaminergic mechanisms in punished and nonpunished behavior.
        J Pharmacol Exp Ther. 1970; 173: 277-283
        • Guy W.
        ECDEW Manual For Psychopharmacology. U.S. Government Printing Office, Washington, DC1976 (Revised. NIMH Publication, DHEW (76-338))
        • Hamilton M.
        The assessment of anxiety states by rating.
        Br J Med Psych. 1959; 32: 50-55
        • Hoehn-Saric R.
        • McLeod D.R.
        Clinical management of generalized anxiety disorder.
        in: Coryell W. Winoker G. The Clinical Management of Anxiety Disorders. Oxford University Press, New York1991: 79-100
        • Jones B.J.
        • Oakley N.R.
        • Tyers M.B.
        The activity of GR 38032F: A 5-HT antagonist in the rat and cynomologous monkey.
        Br J Pharmacol. 1987; 390: 88
        • Kahn R.S.
        • Kalus O.
        • Wetzler S.
        • Van Praag H.M.
        The role of serotonin in the regulation of anxiety.
        in: Brown S.-L. Van Praag H.M. The Role of Serotonin in Psychiatric Disorders. 1991: 129-160 (New York)
        • Murphy D.L.
        Neuropsychiatric disorders and the multiple human brain serotonin subtypes and subsystems.
        Neuropsychopharmacology. 1990; 3: 457-471
        • Reyntjens A.
        • Gelders Y.G.
        • Hoppenbrouwers M.L.
        • Vanden J.A.
        • Bussche G.
        Thymosthenic effects of ritanserin (R55667): A centrally acting serotonin-S2 receptor blocker.
        Drug Dev Res. 1986; 8: 205-211
        • Rickels K.
        • Weisman K.
        • Nostad N.
        • et al.
        Buspirone and diazepam in anxiety: A controlled study.
        J Clin Psychiatry. 1982; 43: 81-88
        • Wise C.D.
        • Berger B.D.
        • Stein L.
        Serotonin: A possible mediator of behavioral suppression induced by anxiety.
        Dis Nerv Syst. 1970; GWAN 31 (suppl): 34-37